



April 18, 2023

MedVenture Partners, Inc.

Additional Investment in Alivas, Inc.

MPI-2 Investment Limited Partnership (MPI), managed and operated by MedVenture Partners, Inc., participated in a 210 million Japanese Yen Series B round of Alivas, Inc.

The prevalence rate of chronic constipation is estimated to be between 14% to 17% of the general population and there are currently approximately 17 million patients in Japan. The current standard of care are lapactic agents, but 75% to 90% of patients are dissatisfied with this treatment due to the lack in efficacy. The alternative treatment, laparoscopic colectomy, has not gained widespread popularity either because of its invasiveness and insufficient improvement of patient QOL.

Alivas, Inc. is a startup company founded by alumni from the Japan Biodesign program and is developing the first device for endovascular treatment of chronic constipation, aiming to provide a minimally invasive treatment option to the patient.

MPI will not only financially support Alivas, Inc.'s product development, but will also continue to name Hajime Oshita, President of MPI, to the Board of Directors to accelerate the development and marketing of their product.

MPI will continue to actively invest in the medical device space while accelerating the growth of medical device startups in Japan, bridging overseas startups and Japanese companies, and contributing to the development of a medical device ecosystem in Japan.

Press Contact:

Saori Yoshida

MedVenture Partners, Inc.

7F Nihonbashi Muromachi Mitsui Tower

Nihonbashi Muromachi 3-2-1 Chuo-ku, Tokyo 103-0022 JAPAN

Tel: +81-3-6273-4437